Kryczka W, Grieb P
Oddział Obserwacyjno-Zakaźny Wojewódkiego Szpitala Zespolonego, Kielcach.
Postepy Hig Med Dosw. 1994;48(1):53-68.
Ursodeoxycholic acid (UDCA) is frequently confused with chenodeoxycholic acid (CDCA), although its pharmacological properties are quite different, clinical indications much broader and it produces practically no side effects. By several mechanisms (including, inter alia, induction of hypercholeresis and formation of liquid crystals with cholesterol) UDCA decreases bile saturation with cholesterol and increases bile metastability. Upon oral administration UDCA, which is hydrophilic, substitutes for and protects hepatocytes against damage by other more hydrophobic and toxic bile acids. In consequence it exerts hepatoprotective and immunocorrective influence. Clinical efficacy of UDCA in gallstone dissolution and prophylaxis, in treatment of biliary dyspepsias, in chronic active hepatitis, in primary biliary cirrhosis and in other cholestatic liver diseases is reviewed. Other therapeutic indications for the drug are also mentioned.
熊去氧胆酸（UDCA）常与鹅去氧胆酸（CDCA）混淆，尽管其药理特性有很大不同，临床适应证更广泛且几乎不产生副作用。通过多种机制（尤其包括诱导胆汁分泌过多以及与胆固醇形成液晶），UDCA降低胆汁中胆固醇的饱和度并增加胆汁的亚稳定性。口服后，亲水性的UDCA可替代并保护肝细胞免受其他疏水性更强且有毒的胆汁酸的损害。因此，它具有肝保护和免疫调节作用。本文综述了UDCA在胆结石溶解与预防、胆汁性消化不良治疗、慢性活动性肝炎、原发性胆汁性肝硬化及其他胆汁淤积性肝病治疗中的临床疗效。文中还提及了该药物的其他治疗适应证。
